NTRK3 and neoplasm: Then, the TMB was evaluated in the ICI-treated LUAD and TCGA-LUAD cohorts, and as expected, it was significantly higher in the NTRK3-MT groups (Figure 3C), consistent with previous studies showing that tumor immunity is positively associated with the TMB.